Skip to content
StockMarketAgent
Direct answer
CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $382, high $743, with mid-point at $561.
Stock analysis

CI CI fair value $382–$743

CI
By StockMarketAgent.AI team· supervised by
분석일: 2026-05-12다음 업데이트: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
주가
$289.07
▲ +272.29 (+94.20%)
공정 가치
$561
$382–$743
등급
적극 매수
confidence 83/100
상승 여력
+94.2%
upside to fair value
안전 마진
$477.16
MoS level · 15%
시가총액
$76.5B
P/E fwd 8.6
영어 원본으로 대체KO
번역하는 동안 영어 원본을 표시 중
이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

§1 개요

  • Composite fair value $561 with high case $743.
  • Implied upside of 94.2% to fair value.
  • Moat 9/10 · confidence 83/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$561
Margin of safety
+48.5%
Confidence
83/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$289.07Price
Low $382.18
Mid $561.36
High $742.98

CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Evernorth scale and specialty pharmacy
    Evernorth scale and specialty pharmacy dominance
  • Vertical integration of PBM and
    Vertical integration of PBM and health benefits
  • Cycle upside
    Consolidation of specialty pharmacy and managed care services driving scale efficiencies.

§2 베어 케이스

Sweeping legislative changes target PBM spread pricing and rebates, crippling Evernorth's profitability. At the same time, sudden medical cost inflation squeezes traditional insurance margins, limiting the cash available to service Cigna's massive debt load.

이 논제가 무너지는 경로

PBM Spread Pricing Ban

· High

Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.

FV impact
Moderate to Severe
Trigger
12-24 months

Medical Cost Spike

· Medium

Unanticipated structural increase in utilization rates compresses medical loss ratios beyond historical norms.

FV impact
Moderate
Trigger
6-12 months

De-leveraging Failure

· Low

Inability to service acquisition-related debt due to sustained margin compression, halting share repurchases.

FV impact
Severe
Trigger
24-36 months
모니터링할 조기 경보 신호
지표현재트리거 임계값
Operating margins sustainably compressing toward the 3.0% industry median over 4 consecutive quarters.MonitorDeterioration versus the report thesis
Total corporate revenue actively dropping into negative YoY growth territory.MonitorDeterioration versus the report thesis
Unplanned suspension of the share repurchase program.MonitorDeterioration versus the report thesis
Medical care ratio (MCR) exceeding internal targets for two consecutive quarters.MonitorDeterioration versus the report thesis
Key enterprise client losses within the Evernorth segment.MonitorDeterioration versus the report thesis

§3 재무 이력

손익계산서 — 최근 6기
항목T−0T−1T−2T−3T−4CAGR
기간2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
매출$174.27B$180.03B$195.19B$244.38B+8.8%
매출총이익
영업이익
순이익$5.37B$6.70B$5.16B$3.43B-10.6%
EPS (희석)$21.30$17.39$12.12$22.18+1.0%
EBITDA
R&D
판관비$13.01B$13.17B$14.82B$14.84B+3.3%

품질 점수

OCF / 순이익
3.02×
>1은 이익의 질이 높음을 의미
회계 품질 게이트
Fail
섹터 조정 게이트
ROIC
7.2%
투하자본수익률
섹션 3

Numbers analysis

현금 흐름

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

자본 배분

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

개인 구독자 — §4부터11개 섹션 더

전체 분석 읽기 — 11개 섹션 더.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

모든 커버 종목에 대한 전체 보고서
24개월 등급 아카이브
관심 목록 브리핑 + 등급 변경 알림
모든 언어로 PDF + DOCX 내보내기
무료 체험 시작
언제든지 취소 가능.
FAQ

CI — frequently asked questions

  1. Based on our latest analysis, CI looks meaningfully undervalued. The current price is $289 versus a composite fair-value midpoint of $561 (range $382–$743), which implies roughly 94.2% upside to the midpoint.
Related coverage

Names readers of CI also follow

Same archetype: mature-compounder